Global Life Science Ventures GmbH

The Swiss venture capital firm has made one internal promotion.

The Swiss venture capital firm has made one internal promotion.

GLSV leads E12m round for Pieris; Optillion takes fundraising to $70m; Opto Speed completes E30m financing round

News about hirings, departures and promotions at GLSV, ETF, Alvarez & Marsal, Foresight, Inflexion, Advent, Clipperton, Wellington, Cavendish, Forbion

Quick profiles of the three venture-backed IPOs that went out on U.S. exchanges in September: Regenxbio, Penumbra and Nabriva Therapeutics.

Nabriva Therapeutics, a biopharmaceutical company focused on treating serious infections, has unveiled its IPO after pricing its 9 million shares at $10.25 per share. The stock began trading Friday on the NASDAQ under the ticker symbol "NBRV." Leerink Partners LLC and RBC Capital Markets are serving as the lead underwriters. Nabriva's backers included Vivo Capital, OrbiMed EcoR1 Capital, HBM, Phase4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund

Biotech company Nabriva Therapeutics AG has closed $120 million in Series B funding. Vivo Capital and OrbiMed led the round with participation from EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM, Phase4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund. In addition to the funding, representatives of Vivo Capital and OrbiMed will join Nabriva's supervisory board.

Holger Reithinger has joined Forbion Capital Partners as a partner and head of the firm's new Munich office. He previously was with Global Life Science Ventures.

Holger Reithinger has stepped down as a partner with Global Life Science Ventures, according to VentureWire. No word yet on his future plans. The European venture firm is planning to restart an earlier attempt to raise €150 million for its third fund.